MOONLAKE IMMUNOTHERAPEUTICS: 10-Q filed 2021-11-12
What MOONLAKE IMMUNOTHERAPEUTICS reported in its quarterly report filed 2021-11-12 (fiscal Q3 2021): 16 published measures, 38 facts as tagged in accession 0001213900-21-058671.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-11-12
- Fiscal period
- fiscal Q3 2021
- Accession
- 0001213900-21-058671 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All MOONLAKE IMMUNOTHERAPEUTICS filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 116,247,146 | USD | |
| At 2020-12-31 | 116,633,898 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 6,084,078 | USD | |
| At 2020-12-31 | 4,150,183 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | -4,836,932 | USD | |
| At 2020-12-31 | -2,516,285 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 1,028,752 | USD | |
| At 2020-12-31 | 1,335,924 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -2,092,025 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -2,320,649 | USD | 273 |
| 2020-08-13 to 2020-09-30 | -5,000 | USD | 49 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | -249,109 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-09-30 | -58,063 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | -4,837,263 | USD | |
| At 2020-12-31 | -2,516,616 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -2,093,506 | USD | 92 |
| 2021-01-01 to 2021-09-30 | -2,346,085 | USD | 273 |
| 2020-08-13 to 2020-09-30 | -5,000 | USD | 49 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 1,206,793 | USD | |
| At 2020-12-31 | 1,618,981 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 2,059,078 | USD | |
| At 2020-12-31 | 125,183 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | -4,836,932 | USD | |
| At 2021-06-30 | -2,744,907 | USD | |
| At 2021-03-31 | -2,592,574 | USD | |
| At 2020-12-31 | -2,516,283 | USD | |
| At 2020-09-30 | 20,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-09-30 | 2,059,078 | USD | |
| At 2020-12-31 | 67,120 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | -2,092,025 | USD | 92 |
| 2021-04-01 to 2021-06-30 | -152,333 | USD | 91 |
| 2021-01-01 to 2021-03-31 | -76,291 | USD | 90 |
| 2020-08-13 to 2020-09-30 | -5,000 | USD | 49 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 2,093,506 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 2,346,085 | USD | 273 |
| 2020-08-13 to 2020-09-30 | 5,000 | USD | 49 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-09-30 | 1,481 | USD | 92 |
| 2021-01-01 to 2021-09-30 | 25,436 | USD | 273 |
Inspect the source
- Entity
- MOONLAKE IMMUNOTHERAPEUTICS / CIK 0001821586
- Captured
- 2026-09-21T17:28:56.515Z
- SEC response SHA-256
5ec7814562ed5c855b3116fa30aee75dd24e176ae565286831b8e7bddfac283a
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001821586.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))